Universal Hepatitis B Vaccination in Adults Aged 19–59 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022

作者：Mark K. Weng, Mona Doshani, Mohammed A. Khan, Sharon E. Frey, Kevin A. Ault, Kelly L. Moore, Eric Hall, Rebecca L. Morgan, Doug Campos‐Outcalt, C. William Wester, Noele P. Nelson · 发表于：MMWR Morbidity and Mortality Weekly Report · 年份：2022 · DOI：10.15585/mmwr.mm7113a1 · 被引用次数：198 · 研究领域：Hepatitis B Virus Studies、Hepatitis C virus research、Hepatitis Viruses Studies and Epidemiology

Hepatitis B (HepB) vaccines have demonstrated safety, immunogenicity, and efficacy during the past 4 decades (1,2). However, vaccination coverage among adults has been suboptimal, limiting further reduction in hepatitis B virus (HBV) infections in the United States. This Advisory Committee on Immunization Practices (ACIP) recommendation expands the indicated age range for universal HepB vaccination to now include adults aged 19-59 years. Removing the risk factor assessment previously recommended to determine vaccine eligibility in this adult age group (2) could increase vaccination coverage and decrease hepatitis B cases.